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Abstract
Background: Malignant canine mammary tumors represent 50% of all neoplasms in female dogs. Matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be involved in tumor
progression, and they are also associated with the reactive stroma, which provides structural and vascular support
for tumor growth.
Results: MMP-2, MMP-9 and MT1-MMP were expressed at both the mRNA and protein levels in tumor samples.
MMP-2 and MMP-9 immunohistochemical reactions were evident both in the epithelial tumor cells and in the
stromal compartment to varying degrees; in particular, the intensity of the MMP-2 staining was stronger in the
stromal fibroblasts close to epithelial tumor cells in simple carcinomas than in adenomas. These data were
supported by gelatin-zymography; bands for the active form of MMP-2 were found in 94% of carcinoma samples,
compared with 17% of benign tumor samples. The gene expression and immunohistochemical results for MT1-
MMP were comparable to those for MMP-2. The immunoreactivity for MMP-13 and TIMP-2 was lower in
carcinomas than in adenomas, confirming the mRNA data for MMP-13 and the other MMP inhibitors that were
evaluated. The active form of MMP-9, but not the active form of MMP-2, was identified in the plasma of all of the
tested dogs.
Conclusions: Our findings suggest that MMP-9, MMP-2 and MT1-MMP, which are synthesized by epithelial cancer
cells and cancer-associated fibroblasts, play an important role in malignant canine mammary tumors. The reduction
of MMP-13 and TIMP-2 could also be a significant step in malignant transformation. MMP-2 and MT1-MMP could
be further evaluated as future biomarkers for predicting the progression and prognosis of canine mammary
tumors.
Background
Mammary neoplasia is one of the most common tumors
in dogs, and malignant types occur in approximately
half of canine mammary tumors. Invasion and metasta-
sis are typical features of carcinomas [1,2]. The physical
process of tumor invasion involves cellular disengage-
ment from the local microenvironment, followed by
degradation of the surrounding matrix and cellular
movement [3]. Invasion and metastasis of malignant
tumor cells is a complex multistep process, in which the
initial events are disruption of the extracellular matrix
(ECM) and invasion of the basement membrane. In
addition, fibroblasts in the stroma of cancerous tissue
can promote the proliferation and invasion of carcinoma
cells and induce angiogenesis via the secretion of several
ECM molecules, proteases and cytokines [4,5]. This
mechanism is highly organized and involves the selective
action of a group of proteases that are active at neutral
pH and can collectively degrade most, if not all, compo-
nents of the ECM [6,7]. These proteases are known as
matrix metalloproteinases (MMPs), and they hydrolyze
the protein and proteoglycan components of the ECM.
Under physiological conditions, MMPs are expressed by
a variety of cells and tissues. MMPs are also involved in
a number of pathological processes and are thought to
be responsible for the accelerated ECM breakdown that
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is associated with tumor invasion and metastasis [8].
Gelatinases are a subgroup within the MMP family and
include MMP-2 and MMP-9. MMPs play the same role
in dogs as in humans, controlling tumor invasion and
progression in different tumors [9-14].
MMP-2 and MMP-9 are secreted in an inactive form,
which is called a zymogen or a pro-MMP. Several types
of inhibitors, called tissue inhibitors of MMPs (TIMPs),
regulate MMP activity. TIMPs also function as MMP
activators [15]. To exert their inhibiting or activating
functions, TIMP-1 and TIMP-2 preferentially bind to
MMP-9 or MMP-2, respectively [16,17]. The unbalanced
activities of MMPs and TIMPs are involved in tumor
progression [18]. Evaluation of the activities of TIMP-1,
TIMP-2 and TIMP-3 in canine mammary tumor sam-
ples by reverse zymography has shown that low activity
can be correlated with a malignant phenotype [14].
Membrane type 1 MMP (MT1-MMP) was the first
MT-MMP to be identified as a major physiological acti-
vator of pro-MMP-2 in humans [9]. Studies of canine
mammary tumors suggest that pro-MMP-2 activation
requires the formation of a ternary complex that con-
sists of the C-terminal domain of pro-MMP-2, TIMP-2
and MT1-MMP [19].
A new MMP inhibitor gene, called reversion-inducing
cysteine-rich-protein with Kazal-motifs or RECK, was
recently identified in dogs [20]; it was reported to be an
endogenous MMP inhibitor and a membrane-anchored
glycoprotein that has no structural homology with
TIMPs but downregulates MMP-2, MMP-9 and MT1-
MMP. RECK has been implicated in tumor progression
[20].
The important role of another MMP family member,
MMP-13, has been demonstrated in human cancer [21].
MMP-13 promotes tumor growth and progression by
mediating ECM reorganization and regulating the biolo-
gical activity of cytokines in skin squamous cell carci-
noma [22], melanoma [23], breast cancer and colorectal
cancer [24,25]. In veterinary medicine, reports of MMP-
13 expression are only available for inflammatory and
degenerative diseases [26,27].
The mRNA expression of MMP-2, MMP-9, TIMP-1,
TIMP-2 and TIMP-3 has been extensively studied in
vivo and in vitro in various human tumors [16,28-30]. In
veterinary medicine, mRNA expression of these genes
has been used to study canine neoplasia [12,20] and
other diseases (e.g., meningitis-arteritis, chronic valvular
disease, and arthritis [31-33]), but their expression in
canine mammary tumors has not been specifically docu-
mented. Thanks to the sequencing of the entire dog
genome, microarray technology has been used to char-
acterize different canine mammary cell lines, progestin-
induced canine mammary hyperplasia and spontaneous
mammary tumors [34-37], but to our knowledge, no
targeted gene expression profiling studies are available
for spontaneous canine mammary tumors.
This report is the first study to consider MMP-2,
MMP-9, MMP-13, MT1-MMP and TIMP-2 expression
at both the mRNA and protein levels in canine mam-
mary tumors including adenomas and carcinomas. The
enzymatic activities of MMP-2 and MMP-9 were quan-
tified by gelatin-zymography of the same homogenized
tumor tissues and plasma from selected patients. Gene
expression was evaluated also for TIMP-1, TIMP-3 and
RECK. Moreover, the stromal compartments in these
tumors were specifically evaluated.
Methods
Tissue sampling
Fresh tissue samples were obtained from 35 dogs that
underwent surgery for mammary neoplasia. The dogs
underwent surgery due to evident disease, and the expli-
cit consent of the owner was obtained. Excised tumor
lesions were immediately divided into aliquots and
stored under diverse conditions for different analytical
techniques. For RNA isolation, aliquots of approximately
100 mg were immersed in RNAlater® solution (Applied
Biosystems, Foster City, CA) and stored at -20°C until
use. For histological examination and immunohisto-
chemistry, the tissue was formalin-fixed and paraffin-
embedded. For gelatin-zymography, aliquots of up to
100 mg were frozen at -20°C until use.
Gene expression
Total RNA was isolated from control mammary glands,
which were obtained from pathogen-free adult Beagles
generously provided by GlaxoSmithKline Manufacturer
S.p.A. (Verona, Italy) that had been used for other
experimental purposes and 35 pathological samples
using TRIzol® (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. The samples were puri-
fied with a classical phenol-chloroform extraction step.
The total RNA concentration and quality were mea-
sured with a Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, DE) and by
denaturing gel electrophoresis.
First-strand cDNA was synthesized from total RNA
using the High Capacity cDNA Transcription Kit
according to the manufacturer’s protocol (Applied Bio-
systems, Foster City, CA).
The generated cDNA was used as the template for
quantitative real-time RT-PCR (qRT-PCR) in a LightCy-
cler 480 Instrument (Roche Diagnostics, Basel, Switzer-
land) using standard PCR conditions. The qRT-PCR
reactions consisted of 1X LightCycler 480® Probe Mas-
ter (Roche Diagnostics, Basel, Switzerland), 300 or 600
nM forward and reverse primers (the primer combina-
tion and final concentrations were optimized during
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assay setup), 100 nM human Universal Probe Library
(UPL) probe (Roche Diagnostics, Basel, Switzerland) and
5 ng cDNA. The primers and human UPL probes
shown in Table 1 were designed using the UPL Assay
Design Centre web service. Calibration curves using a
four-fold serial dilution of a cDNA pool revealed PCR
efficiencies close to two and error values less than 0.2.
Canine transmembrane BAX inhibitor motif containing
4 (CGI-119) and Golgin a 1 (GOLGA1) were chosen as
reference genes for the absence of pathological state-
dependent differences in mRNA expression [38]. Their
amplification efficiencies were approximately equal to
that of the target genes; moreover, no statistically signif-
icant difference was observed in their expression profiles
between healthy and pathological samples. The ΔΔCt
method [39] was used for the relative quantification of
mRNA. Relative quantification (RQ) values were
ultimately expressed as the fold change, such as RQ
sample/control group mean RQ ratio, assuming that the
control mammary gland mean RQ was equal to 1.
Statistical analysis of the gene expression data was per-
formed using the Kruskal-Wallis test followed by
Dunn’s post test. The correlation analysis of the target
gene mRNA data was performed using a Spearman
nonparametric test. In both analyses, GraphPad InStat
2.01 software (San Diego, California, USA) was used,
and a p value < 0.05 was considered significant. Finally,
Grubbs’ test was used to identify outliers.
Immunohistochemistry
To analyze the expression of the MMP-2, MMP-9,
MMP-13, MT1-MMP and TIMP-2 proteins by immu-
nohistochemistry, contiguous 4 μm sections were cut
from blocks of formalin-fixed, paraffin-embedded tissue,
and the sections were placed on charged slides. After
deparaffinization, the primary antibody incubation step
for all antibodies was performed by an automated sys-
tem (Ventana Medical Systems, Tucson, AZ). The perti-
nent antibody details are summarized in Table 2. The
remainder of the staining procedure included incubation
with a biotinylated anti-mouse secondary antibody, the
diaminobenzidine substrate and a hematoxylin counter-
stain was performed using the Ventana ES automated
immunohistochemistry system. Negative control slides
were incubated with isotype-matched immunoglobulin
in parallel with each staining batch to confirm the speci-
ficity of the antibodies. For each antibody, cases were
semi-quantified for each protein-stained area. The inten-
sity and the percentage of immunoassayed tumor cells
were analyzed. Each slide was scanned with a 400 ×
power objective in ten fields per slide, and the fields
were selected by searching for protein-stained areas. A
section was considered negative or positive according to
the absence or presence of cytoplasmic staining. An
intensity score of zero was given if no staining was
detected, one if there was weak to moderate staining,
two if moderate to strong staining was present, and
three if strong staining was detected. A total score for
each examined field was obtained by multiplying the
intensity score by the percentage of immunoassayed
cells. A final ratio was obtained after averaging the ten
selected fields. An image analysis system that consisted
of an Olympus BX51 microscope and software analysis
(analySIS, Soft imaging system, Münster, Germany) was
used. Furthermore, the immunoreactivity of each anti-
body was separately recorded for tumor and stromal
cells in ten fields (400× power objective), and the final
result was expressed as the average percentage from ten
fields. For statistical analysis, dog tumors were subdi-
vided into two groups: benign and malignant.
Table 1 Primer sequences and UPL probes used for qRT-
PCR amplification of selected target and reference genes.
Genes Accession number Primer sequence (5’-3’) UPL
probe
MMP-2 [GenBank:
XM_535300.2]
F: gggaccacggaagactatga
R: atagtggacatggcggtctc
29
MMP-9 [GenBank:
NM_001003219.1]
F:
tgagaactaatctcactgacaagca
R: gctcggccacttgagtgta
6
MMP-13 [GenBank:
XM_536598.2]
F: ctcttcttctcgggaaacca
R: gcctggggtagtctttatcca
50
MT1-
MMP
[GenBank:
XM_843664.1]
F: gatctgaatgggaatgacatctt
R: gatggccgagggatcatt
76
TIMP-1 [GenBank:
NM_001003182.1]
F: cagggcctgtacctgtgc
R: cctgatgacgatttgggagt
112
TIMP-2 [GenBank:
NM_001003082.1]
F:
atgagatcaagcagataaagatgttc
R: ggaggaaggagccgtgtag
93
TIMP-3 [GenBank:
XM_538410.2]
F: tgctgacaggccgcgt
R: gcagttacagcccaggtga
14
RECK [GenBank:
NM_001002985.1]
F: aaggggtgtctgtctggagat
R: cccaatttgcaaccttgaac
97
CGI-119 [GenBank:
XM_531662.2]
F:
tctacaatctaagagagatttcagcaa
R: ttcctgacaagcacaaaatcc
15
GOLGA-
1
[GenBank:
XM_537849.2]
F: ggtggctcaggaagttcaga
R: tatacggctgctctcctggt
149
F: forward; R: reverse
Table 2 Antibody details.
Antigen Source Clone Dilution Manufacturer
MMP-9 Human MAB 3309 1:1000 Chemicon (Millipore)
MMP-2 Human Ab-7 1:400 Neomarkers, Fremont, USA
TIMP-2 Human MAB 3317 1:1000 Chemicon (Millipore)
MMP-13 Human VIIIA2 1:100 Millipore Co., Billerica, USA
MT1-MMP Human - 1:200 Millipore Co., Billerica, USA
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Immunostaining score values for each protein were
expressed as a median (range). The Mann-Whitney test
was used to compare the immunostaining scores. Differ-
ences in percentages were calculated with the Chi-
square test. The program SPSS 17.00 (SPSS Inc, Chi-
cago, IL, USA) was used for all calculations.
Zymography
MMP-2 and MMP-9 activity was studied by zymogra-
phy, which reveals the gelatinase activity of latent
proenzymes (zymogens) and mature MMPs. The
homogenized tissue was centrifuged at 1500 rpm for
10 min, and the protein concentration of the superna-
tant was measured. The sample protein concentration
was adjusted to 1 mg/ml, and 5 μl was diluted 1:1 in
sample buffer; the final 10 μl sample was subjected to
electrophoresis on an 8% SDS-PAGE gel copolymer-
ized with 0.1% gelatin. Following electrophoresis, the
gel was incubated for 1 h at room temperature in a
2.5% Triton X-100 solution and then at 37°C for 16 h
in 0.5 M Tris-HCl buffer, pH 7.4, with 10 mM CaCl2.
The gels were stained with 0.1% Coomassie Brilliant
Blue R-250 and de-stained with 30% methanol and
10% acetic acid. Gelatinolytic activities were detected
as unstained bands against the background of Coomas-
sie-stained gelatin. Culture medium conditioned by
A2058 melanoma cells was used as a control to iden-
tify the pro-MMP-9 gelatinolytic band, while condi-
tioned media from HT1080 fibrosarcoma cells was
used for the active forms of MMP-2 and MMP-9 and
small amounts of the pro-MMP-2 [6]. The amount of
MMP-9 in 20 μl of the A2058 melanoma cell-condi-
tioned media was defined as 100 arbitrary units (a.u.).
The MMP-2 activity in 20 μl of HT1080 fibrosarcoma
cell-conditioned media was defined as 100 a.u. The
bands were quantified using an image analyzer system
that consisted of a GelDoc 2000 and Quantity One
software (BioRad, Hercules, CA, USA).
Peripheral blood samples were collected from 14 dogs
24 h before surgery. The plasma was obtained by blood
sample centrifugation and stored at -20°C, and 10 μl
was used for analysis. The plasma concentrations of
MMP-2 and MMP-9 were evaluated by gelatin-zymogra-
phy. The gelatinolytic activity was defined as the arbi-
trary optical density value of the sample relative to the
optical density value of the control plasma from healthy
dogs.
Results
This study included 35 dogs with a median age of 9.9
years. Of the 35 tumors, 13 were simple adenomas,
and 22 were simple carcinomas, according to the
WHO classification system for canine mammary
tumors [40].
Gene expression
The mRNA expression of MMP-2, MMP-9, MMP-13,
MT1-MMP, TIMP-1, TIMP-2, TIMP-3 and RECK in
mammary tumors and healthy mammary glands was
investigated using a qRT-PCR approach. The overall
results are reported in Table 3. All of the target genes
were expressed in the control and tumor samples, with
the exception of MMP-13, which was weakly expressed
or not amplified in approximately half of the tumor
samples (16 of 35 dogs). No statistically significant dif-
ferences were observed for MMPs and inhibitors among
the studied groups, particularly between benign and
malignant tumors. Spearman correlation analysis was
performed to identify potential relationships between
MMPs and their preferential inhibitors at the transcrip-
tional level and between MMP-2 and its well-known
specific activator (MT1-MMP). Positive correlations
were observed between MMP-2 and MT1-MMP (r =
+0.52, p < 0.01), MMP-2 and TIMP-2 (r = +0.47, p <
0.01), MT1-MMP and TIMP-2 (r = +0.39, p < 0.05),
and MMP-9 and TIMP-1 (r = +0.56, p < 0.001).
Immunohistochemistry
Immunohistochemical staining revealed that MMP-2
and MMP-9 were present in all of the tumors examined.
In all samples, the two MMPs were strongly localized in
the cytoplasm of the tumor epithelial cells (Figure 1a, b,
c). There were significant differences in the immunohis-
tochemical score values for these two markers in benign
and malignant neoplasias (Table 4). An intense immu-
noreaction was especially evident for MMP-2 in carcino-
mas, while the difference in MMP-9 immunolabelling in
adenomas and carcinomas was lower. The MT1-MMP
protein was detected in 21 tumors, and its expression
was higher in malignant tumors. Tissue leukocytes and
Table 3 mRNA expression of MMPs and inhibitors in
control mammary glands and benign and malignant
mammary tumors.
Gene mRNA expression
-fold changes (arbitrary units)
Control mammary
gland
Benign
tumors
Malignant
tumors
MMP-2 1.00 ± 0.46 1.01 ± 0.18 0.76 ± 0.12
MMP-9 1.00 ± 0.30 9.95 ± 4.40 7.23 ± 1.58
MMP-13 1.00 ± 0.28 2.08 ± 0.70 1.27 ± 0.25
MT1-
MMP
1.00 ± 0.24 13.26 ± 6.09 2.82 ± 0.64
TIMP-1 1.00 ± 0.17 4.96 ± 1.27 3.97 ± 0.66
TIMP-2 1.00 ± 0.34 0.49 ± 0.09 0.60 ± 0.09
TIMP-3 1.00 ± 0.35 4.16 ± 1.62 2.38 ± 0.65
RECK 1.00 ± 0.52 3.41 ± 1.77 0.51 ± 0.10
Data are expressed as the mean ± SEM.
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Figure 1 Canine mammary tumors. (a) Epithelial tumor cells and stromal fibroblasts with intense MMP-2 immunopositivity in a carcinoma. (b)
Epithelial tumor cells with weak MMP-2 immunopositivity in an adenoma. (c) Epithelial tumor cells and fibroblasts strongly MMP-9-
immunolabelled in a carcinoma. (d) Epithelial tumor cells and stromal fibroblasts with intense MT1-MMP immunopositivity in a carcinoma. (e)
Moderate TIMP-2 immunostaining in epithelial tumor cells in an adenoma. (f) TIMP-2 antibody-negative epithelial tumor cells in a carcinoma.
(immunohistochemistry, 200×).
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plasma cells stained positive for MMP-2 and MMP-9
as well as for MT1-MMP, which was considered a
positive control. Immunohistochemical staining
revealed that TIMP-2 and MMP-13 were more highly
expressed in simple adenomas than in simple carcino-
mas (Figure 1e, f).
The magnitude of the immunohistochemical detection
of MMP-2, MMP-9 and MT1-MMP varied in the fibro-
blasts of the stromal compartment. The staining inten-
sity for MMP-2 and MT1-MMP (Figure 1d) was
stronger in the fibroblasts closest to the epithelial tumor
cells in the malignant tumors, while the fibroblasts that
were immunolabelled by the antibodies for the two pro-
teins were scattered in the adenomas (Table 5). The per-
centage of fibroblasts that were positive for MMP-9
staining was lower than the percentage that were
positive for MMP-2 in carcinomas. The percentage of
TIMP-2- and MMP-13-positive fibroblasts was higher in
adenomas than in carcinomas. The immunohistochem-
ical data are summarized in Tables 4 and 5.
Zymography
For each tumor sample, the active and inactive forms of
MMP2 and MMP-9 were measured by their gelatinolytic
activities (Figure 2). The activities of MMP-2 and MMP-
9 were calculated in arbitrary units per 10 ng of protein.
The pro-MMP-2 band was detected in all samples
examined (adenoma and carcinoma). The activity of the
carcinoma samples ranged between 16.7 and 59.9 units,
while the activity of the adenoma samples ranged
between 3.5 and 15.7 units. Bands for the active form of
MMP-2 were found in 94% of the carcinoma samples
and 17% of the benign tumor samples. In the simple
carcinomas, the MMP-2 activity ranged between 47.4
and 87.5 units. The pro-MMP-9 band was expressed in
all samples examined by gelatin-zymography. The activ-
ity range of the carcinoma samples varied greatly (from
7.5 to 106.4 units), while the activity range of the twelve
benign samples was between 20.5 and 41.2 units. Only
eight carcinomas exhibited bands for the active form of
MMP-9. The activity was similar among the samples,
ranging from 34.3 to 40.3 units. No bands were
observed for the active form of MMP-9 in adenomas.
The activities of both the pro- and activated forms of
MMP-2 and MMP-9 were measured by gelatin-zymo-
graphy of the plasma of fourteen dogs with mammary
tumors and three healthy control dogs. A representative
gel is shown in Figure 3. Regardless of the tumor type,
the band for pro-MMP-9 was significantly more evident
in the plasma of dogs with tumors than in healthy dogs.
The activated form of MMP-9 was not observed in
healthy dogs but was present in all of the dogs with
tumors. Pro-MMP-2 was detectable in the plasma of all
dogs with tumors and also in control dogs with no dif-
ference in the level of expression, and the MMP-2 acti-
vated form was not detectable in either case.
Discussion
In recent years, investigations of tumor growth have
focused on the surrounding stroma in different tumors,
which is important for cellular invasion, tumor growth
and the epithelial mesenchymal transformation [41,42].
The engagement of the neoplasia with a ‘reactive
stroma’ provides structural and vascular support for
tumor growth and also leads to tissue reorganization
and invasiveness [3]. MMPs play an important role in
this mechanism by degrading the stromal connective tis-
sue and basement membrane components. In addition,
MMPs impact tumor cell behavior in vivo because of
their ability to cleave growth factors, cell adhesion
Table 4 Immunostaining score values for MMPs and
TIMP-2 in benign and malignant mammary tumors,
expressed as the median (range).
Protein Immunostaining score values
(median and range)
p values
Benign tumors Malignant tumors
MMP-2 58.5 (45.4-145.5) 179.4 (120.1-267.3) 0.002
MMP-9 78 (26.8-189) 101.1 (34.3-213.9) 0.01
MMP-13 84.2 (0-198.2) 45.3 (0-101.2) 0.005
MT1-MMP 65.3 (0-230.2) 132.1 (34.2-221.2) 0.002
TIMP-2 74.3 (21.2-201.2) 48.9 (0-136.6) n.s.
n.s. = not significant
Table 5 Immunohistochemical score for epithelial tumor
cells and fibroblasts in benign and malignant mammary
tumors, expressed as the average percentage from ten
fields.
Protein Cell type Immunohistochemical score (%) p
value
Benign
tumors
Malignant
tumors
MMP-2 Tumor
cells
88.6 67.5 0.05
Fibroblasts 11.4 32.5
MMP-9 Tumor
cells
84.1 89.4 0.002
Fibroblasts 15.9 10.6
MMP-13 Tumor
cells
56.4 65.9 n.s.
Fibroblasts 43.6 34.1
MT1-
MMP
Tumor
cells
80.3 55.8 0.001
Fibroblasts 19.7 44.2
TIMP-2 Tumor
cells
53.3 79.6 n.s.
Fibroblasts 46.7 20.4
n.s. = not significant
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molecules, and chemokines. The proteolytic activity of
MMPs can be regulated at different levels, including
gene expression, the conversion of the zymogen to the
active enzyme, and by the presence of specific inhibitors.
Among MMPs, MMP-2 and MMP-9 have mainly been
associated with malignant tumor progression and metas-
tasis in both human and canine tumors [12,19,43]. In
this study, the mRNA and protein levels of MMP-2,
MMP-9, MMP-13, MT1-MMP and TIMP-2 in benign
and malignant mammary tumors were thoroughly ana-
lyzed. We then analyzed TIMP-1, TIMP-3 and RECK
mRNA expression and focused on the expression of dif-
ferent MMP proteins in stromal fibroblasts to identify a
possible role in canine mammary tumors.
MMP-2 mRNA was expressed in all pathological sam-
ples, but no statistically significant differences were
observed between benign and malignant tumors. On the
contrary, at the protein level, immunohistochemistry
identified higher MMP-2 expression in carcinomas;
gelatin-zymography confirmed differences in MMP-2
production between adenomas and carcinomas (p <
0.05, data not shown). In particular, significant bands
were observed for both the inactive and active forms of
MMP-2 in simple carcinomas, while simple adenomas
were characterized by minimal bands that corresponded
to pro-MMP-2, suggesting that this enzyme is important
during the infiltration process. Pro-MMP-2 may be con-
verted to the active form during the infiltration process
in malignancy; intense gelatinolytic activity has been
described as necessary for malignant transformation
[44]. These data are comparable to those from human
studies. In human lung and gastric carcinomas, the
MMP-2 activation ratio is enhanced; in canine tumor
studies, higher MMP-2 and MMP-9 levels were
observed in tumors than in inflammation, in malignant
tumors than in benign tumors, in sarcomas than in
Figure 2 Zymographic assay of gelatinase activity in malignant (M) mammary neoplasia, in benign (B) mammary neoplasia and in the
control (C). Bands corresponding to latent and active forms of MMP-9 and to latent and active forms of MMP-2 were observed in carcinomas
(M), while bands corresponding to latent forms of MMP-9 and MMP-2 were observed in adenomas (B). HT1080 fibrosarcoma cells (C) were used
as the control for pro-MMP-9, pro-MMP-2 and active form of MMP-2.
Figure 3 Zymographic assay of gelatinase activity in pre-surgery plasma samples. (M = malignant mammary neoplasia, B = benign
mammary neoplasia, C = control, N = normal dog). Bands corresponding to pro-MMP-2, pro-MMP-9 and active form of MMP-9 were observed
in dogs with adenomas and carcinomas (B, M). Bands corresponding to pro-MMP-9 and pro-MMP-2 were observed in the control dog, and
A2058 melanoma cells (C) were used as the control for active MMP-9.
Aresu et al. BMC Veterinary Research 2011, 7:33
http://www.biomedcentral.com/1746-6148/7/33
Page 7 of 10
carcinomas and in the advancing edge of canine malig-
nances than in the center of canine tumors [11]. In this
study a band corresponding to active MMP-2 was
observed in only two adenomas, and histological exami-
nation of these two samples showed an intense stromal
reaction close to the tumor.
Activation of the zymogen form of MMP-2 is a cell-
surface event that is mediated by members of the mem-
brane-type subfamily of MMPs, and MT1-MMP is the
first physiological activator of pro-MMP-2 [45]. In this
study, the immunohistochemical data for MMP-2 and
MT1-MMP were comparable for both adenomas and
carcinomas. MT1-MMP was distributed similarly to
MMP-2 in malignant tumors and was reduced in benign
tumors. Despite the opposing results obtained for
mRNA and protein expression in benign and malignant
mammary tumors, a close relationship between MMP-2
and MT1-MMP was observed at the pre-transcriptional
level. Interestingly, immunohistochemistry showed an
intense reaction for the stromal fibroblast component,
with a significant increase in MMP-2 (p = 0.05) and
MT1-MMP (p = 0.001) expression in the fibroblasts
associated with carcinoma. MT1-MMP expression gen-
erally correlates well with MMP-2 activation in various
human cancers, suggesting that MT1-MMP plays an
important role in cancer cell invasion [46,47]. This pre-
sumably occurs through direct ECM cleavage by MT1-
MMP and perhaps via MT1-MMP-mediated pro-MMP-
2 activation. Both MMP-2 and MT1-MMP have pre-
viously been detected by immunohistochemistry in
canine mammary carcinomas [19]. Our results were
similar, suggesting that peritumor stromal cells may be
a possible source of MMP-2 and MT1-MMP and pro-
moters of invasion. Further studies in different tumors
or in vitro are needed to support this hypothesis.
qRT-PCR analysis revealed a high level of mRNA
expression for MMP-9 in both benign and malignant
mammary tumors. Epithelial cell immunoreactivity with
the anti-MMP-9 antibody was observed in all tumors.
MMP-9 positivity was higher in malignant tumors than
in adenomas, confirming previous observations in
human breast cancer [10] and canine mammary tumors
[13]. Immunohistochemistry also revealed that the stro-
mal fibroblasts had a minimal capacity to synthesize
MMP-9. The enzyme activity was analyzed by gelatin-
zymography; active MMP-9 form was not observed in
any of the simple adenomas, and only eight carcinomas
had a band for the active MMP-9 form, while all of the
examined tumors had variable pro-MMP-9 gelatinolytic
activity (p < 0.01 data not shown). The limited presence
of the active form of MMP-9 may indicate a minor role
for this gelatinase within the tumor, and it appears to be
of little prognostic or pathogenetic value, as observed in
canine tumors [11].
TIMP-2 plays a double role, as both inhibitor and
activator of MMP-2. Surprisingly, high TIMP-1 and
TIMP-2 mRNA levels can predict adverse prognosis and
be correlated with tumor aggressiveness in several dif-
ferent human cancers, including breast cancer [43,48].
In our study, neither the mRNA nor the protein levels
of TIMP-2 expression correlated with malignancy.
MMP-13 was also evaluated in our study. At the pre-
transcriptional level, it was expressed only in half of
pathological samples, and immunohistochemistry
revealed a higher level of expression in benign tumors
than in malignant tumors. MMP-13 expression has pre-
viously been evaluated only in human tumors, for which
MMP-13 involvement in tumor invasiveness was unclear
[21].
MMP-2 and MMP-9 plasma levels have been reported
to be elevated in patients with various types of cancer.
In our study, plasma gelatinolytic activity in dogs was
estimated by gelatin zymography. Pro-MMP-9 and pro-
MMP-2 were significantly concentrated in the plasma of
all of the dogs, and bands for the latent forms were pre-
sent in both animals with adenoma and animals with
carcinoma. Moreover, the active form of MMP-9 was
present in the plasma of all of the dogs with tumors
with no differences in concentration between benign
and malignant neoplasias. These data could indicate that
the plasma level of active MMP-9 is consistent with a
proteinase activity that is due to the presence of an
“ongoing disease,” and MMP-9 plasma levels may be a
feasible method for detecting neoplastic growth in dogs
in the future.
TIMP-1, TIMP-3 and RECK mRNA expression were
also evaluated and no statistically significant differences
were observed among the groups. Contrasting results
are reported in literature: microarray studies in dogs
have shown that TIMP-1 and TIMP-3 are inhibited in
progestin-induced canine hyperplasia relative to normal
mammary glands [37]. Besides, a qRT-PCR study of
RECK mRNA expression in various spontaneously
developing canine tumors showed that expression levels
were low in the majority of tumor tissues relative to
normal tissues; however, in some neoplasias, RECK
expression was higher than in the controls [47].
To exert its MMP inhibitory or activating role, TIMP-
1 binds preferentially to MMP-9, and TIMP-2 binds to
MMP-2 [16,17]. This relationship was confirmed in this
study by the statistically significant correlations that
were found between MMP-2 and TIMP-2, MMP-9 and
TIMP-1 and MT1-MMP and TIMP-2 mRNA.
Conclusion
The observed discrepancy between the mRNA and pro-
tein data has also been described by other studies [49].
Enzyme accumulation that is not accompanied by an
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increase in mRNA could be due to a feedback mechan-
ism that shuts off mRNA expression after the secretion
and/or binding of the protein. In addition, the samples
used may not be representative [49]. Extracting and
amplifying mRNA from cells obtained through the laser
capture microdissection of the same formalin-fixed tis-
sue that was used for immunohistochemistry might bet-
ter clarify the mRNA/protein expression discrepancy
observed in our study.
In conclusion, we have evaluated the involvement of
MMP-2, MT1-MMP, MMP-9 and various TIMPs in
canine mammary tumors, with an emphasis on the stro-
mal compartment. The present work opens the possibi-
lity of developing new therapies and supports the use of
the dog as an animal model in this field for studying the
role of MMP-2 and MT1-MMP in the mechanism of
cancer. MMPs may be target molecules of the switch
mechanism that leads to the progression of carcinomas
from adenomas.
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